COST-EFFECTIVENESS OF BEVACIZUMAB VERSUS CETUXIMAB VERSUS PANITUMUMAB COMBINED WITH FIRST-LINE FOLFOX FOR METASTATIC COLORECTAL CANCER IN BRAZIL

被引：0
|
作者：
Sasse, Andre [1 ]
Carvalho, Adriana [1 ]
机构：
[1] Univ Estadual Campinas, UNICAMP, Ctr Evidence Oncol, CEVON, Campinas, SP, Brazil
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：100 / 100
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness Analysis of Panitumumab Compared with Bevacizumab for First-Line Treatment of Patients with Wild-Type RAS Metastatic Colorectal Cancer in Germany
    Frank, M.
    Lange, A.
    Michailov, G.
    Lebioda, A.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2016, 21 (04): : 203 - 209
  • [22] Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study
    Marques, Rui Pedro
    Godinho, Ana Rita
    Heudtlass, Peter
    Pais, Helena Luna
    Quintela, Antonio
    Martins, Ana Paula
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (05) : 1321 - 1334
  • [23] Comparative effectiveness of bevacizumab versus cetuximab in patients with metastatic colorectal cancer
    Su, Yi-Chia
    Yang, Yea-Huei Kao
    Wu, Chih-Chien
    Su, Chien-Chou
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 103 - 103
  • [24] Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study
    Rui Pedro Marques
    Ana Rita Godinho
    Peter Heudtlass
    Helena Luna Pais
    António Quintela
    Ana Paula Martins
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1321 - 1334
  • [25] Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer
    Berry, Kristin
    Bensink, Mark Eliot
    Musa, Zahra
    Shankaran, Veena
    Lin, Edward H.
    Ladabaum, Uri
    Bodnar, Carolyn
    Birt, Michael
    Ramsey, Scott David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB FOR FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN WT RAS PATIENTS IN SPAIN
    Suarez, J.
    VALUE IN HEALTH, 2015, 18 (07) : A460 - A460
  • [27] Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer
    Franken, M. D.
    van Rooijen, E. M.
    May, A. M.
    Koffijberg, H.
    van Tinteren, H.
    Mol, L.
    ten Tije, A. J.
    Creemers, G. J.
    van der Velden, A. M. T.
    Tanis, B. C.
    Groot, C. A. Uyl-de
    Punt, C. J. A.
    Koopman, M.
    van Oijen, M. G. H.
    EUROPEAN JOURNAL OF CANCER, 2017, 75 : 204 - 212
  • [28] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER
    Graham, C. N.
    Hechmati, G.
    Hjelmgren, J.
    De Liege, F.
    Lanier, J.
    Knoof, A.
    Knox, H.
    Barber, B.
    de Pouvourville, G.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [29] COST-EFFECTIVENESS OF CETUXIMAB AND BEVACIZUMAB IN THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) FOR PATIENTS WITH KRAS WILD-TYPE TUMOURS IN THE UNITED KINGDOM
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A447
  • [30] Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With KRas Wild-Type Tumours in the United Kingdom
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S264 - S264
12345